# US 12,226,455 B2 · Medical composition for treating cardiac wasting and cachexia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,226,455 B2
- Document ID: US12226455B2
- Status: Granted
- Kind: B2
- Application number: 17/776,749
- Filed: 2020-11-16
- Published: 2022-12-22
- Granted: 2025-02-18
- Earliest claimed: 2019-11-16
- Assignees: RELAXERA Pharmazeutische GmbH & Co. KG
- Applicants: RELAXERA Pharmazeutische GmbH & Co. KG
- Inventors: Thomas Bernd Dschietzig
- Web page: https://patentgrep.com/patent/US12226455B2

## CPC

- A61K 38/2221: {Relaxins}
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/02: Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Human relaxin-2 as active ingredient in a pharmaceutical composition for treating a subject suffering from cachexia syndrome or cardiac wasting or suspected of being at risk of suffering from cardiac wasting or cardiac decompensation is described. Also described are methods of diagnosis of cachexia and cardiac wasting and patients suspected of being at risk of suffering from cardiac decompensation. Further described is a patch pump for sc. or iv infusion of relaxin or human relaxin-2.

## Claims

### Claim 1

A method of treating a patient diagnosed with cardiac wasting or cardiac cachexia or being at risk of cardiac wasting, comprising the administration of an effective amount of human relaxin-2, wherein said method comprises administering human relaxin-2 at 10 to 100 μg relaxin-2/kg body weight/day.

### Claim 2 (depends on 1)

The method of claim 1, wherein the patient is diagnosed when having a sustained ventricular tachycardia of greater than 80 to 100 bpm and/or having an increased resting heart rate of greater than 80 bpm and/or having elevated levels of troponin in blood or serum or plasma, which is greater than the 90th percentile of a standard normal distribution and/or an N-terminal prohormone B-type natriuretic peptide (NTproBNP) level in blood or serum or plasma which is greater than 1000 pg/ml.

### Claim 3 (depends on 1)

The method of claim 1, which comprises administering human relaxin-2 at 25 μg/kg body weight/day.

### Claim 4 (depends on 1)

The method of claim 1, which comprises subcutaneous or intravenous infusion of human relaxin-2 at a rate of 10 to 100 μg/kg body weight/day.

### Claim 5 (depends on 1)

The method of claim 1, which comprises subcutaneous or intravenous infusion of human relaxin-2 at a rate of 25 μg/kg body weight/day.

### Claim 6 (depends on 1)

The method of claim 1, which comprises administering said human relaxin-2 with a patch pump prefilled with a pharmaceutical composition comprising human relaxin-2.